Targets › WISP1
1 program from 1 company in 1 trial: 1 Phase 2; Respiratory; next expected readout Aug 2027.
Downstream regulator in the Wnt/Frizzled-signaling pathway. Associated with cell survival. (UniProt, O95388)
Open in Phaseline: the race on WISP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mediar Therapeutics | MTX-463 IgG1 monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1 | WISP1 | Phase 2 | Idiopathic Pulmonary Fibrosis | Aug 2027 |
Idiopathic Pulmonary Fibrosis (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.